Hepatitis C News and Research

Latest Hepatitis C News and Research

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

AbbVie today announced that the Japanese Ministry of Health, Labour and Welfare has granted priority review for its investigational, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir.

16 Apr 2015

New herbal tea to treat malaria in Africa

Malaria is a critical health problem in West Africa, where traditional medicine is commonly used alongside modern healthcare practices. An herbal remedy derived from the roots of a weed, which was traditionally used to alleviate malarial symptoms, was combined with leaves and aerial portions from two other plants with antimalarial activity, formulated as a tea, and eventually licensed and sold as an antimalarial phytomedicine.

15 Apr 2015

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Research suggests that virological, serological and histological outcomes are comparable between cirrhotic and noncirrhotic patients with chronic hepatitis B virus infection undergoing long-term tenofovir disoproxil fumarate treatment.

13 Apr 2015

Study explores the impact of costly hepatitis C drugs on Rhode Island's prison system

A new study finds that effective new hepatitis C drugs are so expensive the state of Rhode Island would have to spend almost twice its entire prison health budget to treat all its chronically infected inmates.

10 Apr 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26.

8 Apr 2015

Outpatient treatments with fewer injections produce similar results to standard treatment course

Giving fewer antibiotic injections to young infants in the developing world with severe infections such as pneumonia and sepsis is just as safe and effective as the standard course of twice daily injections over the course of a week, according to new Johns Hopkins School of Public Health research conducted in Bangladesh.

6 Apr 2015

Survey reveals growing needs, challenges faced by health plans serving vulnerable populations

Health Integrated, a leader in precision care management solutions, released the results today of an annual health plan survey jointly commissioned with the Association for Community Affiliated Plans, a national trade association representing nonprofit safety net health plans.

6 Apr 2015

Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

Biotest Pharmaceuticals Corporation (BPC), a leading developer of immunology biotherapeutic products, is pleased to announce the relocation of its plasma collection center to 618 NW Loop 410 Suite 101 San Antonio, Texas.

3 Apr 2015

New resource available to help older Chinese Americans better understand their healthcare needs

On the eve of National Minority Health Month, which helps raise awareness for disparities in health and care among minorities in the U.S., a new resource is available to help one such group, older Chinese Americans, better understand and drive their own well-being.

3 Apr 2015

New HCV therapies cost-effective in specific groups of HCV-infected patients

A study led by Boston Medical Center researchers demonstrates that while new therapies to treat Hepatitis C Virus (HCV) are highly effective, they are cost-effective and provide the greatest value in specific groups of HCV-infected patients.

31 Mar 2015

WHO report: Access to new medicines requires transparency, collaboration

As the number of new medicines introduced in Europe rises, governments are finding it increasingly difficult to afford them, according to a comprehensive study released today by the WHO Regional Office for Europe.

27 Mar 2015

Study: HBV exposure increases immune system maturation of infants

A Singapore led study has shown that Hepatitis B Virus Infection (HBV) exposure increases the immune system maturation of infants, which may give a better survival advantage to counteract bacterial infection during early life. These findings radically modify the way that HBV vertical infection of neonates (mother-to-child) is portrayed, and present a paradigm shift in the approach to treatment of patients with chronic hepatitis B.

26 Mar 2015

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab.

19 Mar 2015

New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness analysis led by researchers at The University of Texas MD Anderson Cancer Center.

17 Mar 2015

New vaccine for post exposure treatment of rabies infection enters human clinical trial

Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on the research, development, manufacturing, sales and marketing of vaccine products, announced that a new vaccine for the post exposure treatment of the rabies infection was entering human clinical trial after a six-year long collaboration with a number of research institutes worldwide.

16 Mar 2015

Long-term entecavir, TDF effective in chronic HBV in real-world setting

A Turkish clinical practice study shows that entecavir and tenofovir disoproxil fumarate can effectively maintain long-term virological and biochemical responses in patients with chronic hepatitis B virus infection, both in those with and without cirrhosis.

13 Mar 2015

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

Hepatitis B surface antigen and hepatitis B core-related antigen levels can predict long-term response to sequential nucleos(t)ide analogue and interferon-α therapy in patients with chronic hepatitis B virus infection, research indicates.

13 Mar 2015

HBV genotype C HBeAg seroconversion rate ‘negligible’

Patients with chronic hepatitis B virus genotype C infection who are positive for hepatitis B e antigen should not delay antiviral treatment in the hope of seroconversion, Korean researchers recommend.

13 Mar 2015

Ebola crisis increases susceptibility to measles, other vaccine-preventable illnesses

Johns Hopkins Bloomberg School of Public Health researchers say that major disruptions in the health care systems in West Africa caused by the Ebola crisis have led to significant decreases in vaccinations for childhood diseases, increasing susceptibility to measles and other vaccine-preventable illnesses.

13 Mar 2015

Hepatitis C News and Research

Latest Hepatitis C News and Research

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

New herbal tea to treat malaria in Africa

No effect of baseline cirrhosis on long-term TDF treatment outcomes

Study explores the impact of costly hepatitis C drugs on Rhode Island's prison system

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Outpatient treatments with fewer injections produce similar results to standard treatment course

Survey reveals growing needs, challenges faced by health plans serving vulnerable populations

Biotest Pharmaceuticals relocates its plasma collection center to San Antonio, Texas

New resource available to help older Chinese Americans better understand their healthcare needs

New HCV therapies cost-effective in specific groups of HCV-infected patients

WHO report: Access to new medicines requires transparency, collaboration

Study: HBV exposure increases immune system maturation of infants

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Janssen announces acquisition of XO1

New hepatitis C drugs to place economic burden on health care system, predicts MD Anderson study

New vaccine for post exposure treatment of rabies infection enters human clinical trial

Long-term entecavir, TDF effective in chronic HBV in real-world setting

Factors predictive of sequential nucleos(t)ide analogue, IFN-α therapy response identified

HBV genotype C HBeAg seroconversion rate ‘negligible’

Ebola crisis increases susceptibility to measles, other vaccine-preventable illnesses

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in